LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by BBR Partners LLC

BBR Partners LLC increased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 100.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,000 shares of the company’s stock after purchasing an additional 20,000 shares during the period. BBR Partners LLC owned 0.15% of LENZ Therapeutics worth $950,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MetLife Investment Management LLC purchased a new stake in LENZ Therapeutics during the 3rd quarter worth about $182,000. The Manufacturers Life Insurance Company acquired a new stake in shares of LENZ Therapeutics during the 3rd quarter worth about $743,000. Charles Schwab Investment Management Inc. lifted its stake in LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after purchasing an additional 81,901 shares during the last quarter. GSA Capital Partners LLP acquired a new position in LENZ Therapeutics in the third quarter valued at approximately $246,000. Finally, SG Americas Securities LLC acquired a new position in LENZ Therapeutics in the third quarter valued at approximately $107,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Stock Up 2.9 %

Shares of NASDAQ:LENZ opened at $37.30 on Thursday. LENZ Therapeutics, Inc. has a one year low of $14.42 and a one year high of $38.93. The company has a 50-day simple moving average of $28.20 and a 200-day simple moving average of $22.98.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same period in the previous year, the company earned ($1.33) EPS. Sell-side analysts predict that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.